HANMI PHARM.
HANMI PHARM, officially known as Hanmi Pharmaceutical Co., Ltd., is a leading player in the global pharmaceutical industry, headquartered in KP. Established in 1973, the company has made significant strides in research and development, particularly in the fields of oncology, diabetes, and autoimmune diseases. With a strong presence in both domestic and international markets, HANMI PHARM is renowned for its innovative drug formulations and advanced biopharmaceuticals. Their core products, including unique oral medications and biologics, set them apart through their efficacy and safety profiles. Recognised for its commitment to quality and innovation, HANMI PHARM has achieved notable milestones, including strategic partnerships and successful product launches that enhance its market position. As a forward-thinking organisation, it continues to contribute to the advancement of healthcare solutions worldwide.
DitchCarbon Score
How does HANMI PHARM.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HANMI PHARM.'s score of 48 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
HANMI PHARM.'s reported carbon emissions
In 2023, HANMI PHARM. reported total carbon emissions of approximately 82,550,000 kg CO2e, comprising 11,520,000 kg CO2e from Scope 1, 49,719,000 kg CO2e from Scope 2, and 82,555,000 kg CO2e from Scope 3 emissions. This marked a significant increase in emissions compared to previous years, reflecting the complexities of managing emissions across all scopes. In 2022, the company recorded total emissions of about 60,118,000 kg CO2e, with Scope 1 emissions at 10,762,000 kg CO2e, Scope 2 at 49,358,000 kg CO2e, and Scope 3 at 40,801,000 kg CO2e. This indicates a trend of increasing emissions over the years, with 2021 showing total emissions of approximately 59,544,000 kg CO2e. Despite the rising emissions, HANMI PHARM. has not publicly disclosed specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of defined reduction strategies suggests a need for enhanced climate commitments within the pharmaceutical industry context, where sustainability is becoming increasingly critical. Overall, while HANMI PHARM. has made strides in transparency regarding their emissions data, the lack of concrete reduction targets highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,523,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 58,287,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HANMI PHARM. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
